Ratings Bioretec Oy

Equities

BRETEC

FI4000480454

Market Closed - Nasdaq Helsinki Other stock markets 08:17:33 16/05/2024 pm IST			5-day change	1st Jan Change
2.69 ^EUR	-1.10%		-0.74%	+12.08%

05/04	Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors	CI
22/03	Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
BIORETEC OY	+12.08%	60.12M	-
SHOCKWAVE MEDICAL, INC.	+73.64%	12.42B	B-
PENUMBRA, INC.	-19.88%	7.94B	C+
MASIMO CORPORATION	+2.90%	6.17B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+13.65%	5.5B	D+
APT MEDICAL INC.	+40.00%	5.01B	-
GETINGE AB	-15.25%	4.88B	B
ASAHI INTECC CO., LTD.	-16.42%	4.2B	B-
INARI MEDICAL, INC.	-28.70%	2.73B	C
NOVOCURE LIMITED	+48.49%	2.27B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes